- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Oligodendrogliomas.
Displaying page 1 of 1.
| EudraCT Number: 2007-000386-38 | Sponsor Protocol Number: TEMODAL | Start Date*: 2007-04-26 | |||||||||||
| Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
| Full Title: PRIMARY CHEMOTHERAPY WITH AN EXTENDED SCHEDULE OF TEMOZOLOMIDE (1 WWEK ON / 1 WEEK OFF) FOR LOW GRADE OLIGODENDROGLIAL TUMORS AT RELAPSE OR PROGRESSION AFTER SURGERY: PHASE II TRIAL | |||||||||||||
| Medical condition: GRADE II OLIGODENDORGLIOMAS AND OLIGOASTROCYTOMA AT RELAPSE OR PROGRESSION | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-017422-39 | Sponsor Protocol Number: 26091 | Start Date*: 2010-12-23 | |||||||||||||||||||||
| Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||||||||||||
| Full Title: Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial. | |||||||||||||||||||||||
| Medical condition: Recurrent grade II and grade III gliomas | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Completed) DE (Completed) BE (Completed) GB (Completed) IT (Completed) AT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2013-003668-30 | Sponsor Protocol Number: KCP-330-004 | Start Date*: 2013-11-12 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Karyopharm Therapeutic, Inc. | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients with Recurrent Gliomas | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Recurrent glioblastoma or other brain cancer after failure of radiation therapy and temozolomide | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DK (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2008-007295-14 | Sponsor Protocol Number: 26081-22086 | Start Date*: 2010-11-17 | ||||||||||||||||||||||||||
| Sponsor Name:European Organization for Research and Treatment of Cancer (EORTC) | ||||||||||||||||||||||||||||
| Full Title: Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma. | ||||||||||||||||||||||||||||
| Medical condition: Newly Diagnosed Anaplastic Glioma with Chromosomal co-deletions of 1p and 19q | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: NL (Prematurely Ended) BE (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2009-011898-33 | Sponsor Protocol Number: HIT-HGG-CilMetro | Start Date*: 2011-11-28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Martin-Luther-Universität Halle-Wittenberg | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Treatment of relapsed or refractory high grade gliomas and diffuse intrinsic pontine gliomas in paediatric patients ≥ 3 years and < 18 years of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2007-000128-42 | Sponsor Protocol Number: HIT-HGG-2007 | Start Date*: 2009-03-19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Martin-Luther-University Halle-Wittenberg | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children ≥ 3 years and adole... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: 1st line therapy of newly diagnosed, previously untreated high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents ≥ 3 years and < 18 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) AT (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2010-022189-28 | Sponsor Protocol Number: BO25041 | Start Date*: 2011-08-12 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A PHASE II OPEN-LABEL, RANDOMIZED, MULTI- CENTRE COMPARATIVE STUDY OF BEVACIZUMAB-BASED THERAPY IN PAEDIATRIC PATIENTS WITH NEWLY DIAGNOSED SUPRATENTORIAL, INFRATENTORIAL CEREBELLAR, OR PEDUNCULAR ... | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Newly diagnosed high-grade glioma | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) AT (Completed) CZ (Completed) DE (Completed) GB (Completed) SE (Completed) HU (Completed) FR (Completed) ES (Completed) DK (Completed) FI (Prematurely Ended) NL (Completed) IT (Completed) PL (Completed) Outside EU/EEA | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2018-005027-16 | Sponsor Protocol Number: NOA-18 | Start Date*: 2020-09-16 | ||||||||||||||||
| Sponsor Name:Heidelberg University Hospital Represented in law by its Commercial Managing Director | ||||||||||||||||||
| Full Title: Improvement of functional Outcome for patients with newly diagnosed grade 2 or 3 glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial | ||||||||||||||||||
| Medical condition: WHO grade 2 or 3 glioma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2021-001672-42 | Sponsor Protocol Number: 0627-19 | Start Date*: 2021-03-26 | |||||||||||
| Sponsor Name:Intas Pharmaceuticals Ltd | |||||||||||||
| Full Title: A Multicentre, Open Label, Balanced, Randomized, Single-Dose, Two-Stage, Two-Treatment, Two-Period, Two-Sequence, Two-Way, Cross-Over Study To Evaluate Comparative Bioavailability Of Temozolomide P... | |||||||||||||
| Medical condition: Patients of malignant gliomas under-going treatment with temozolomide under fasting conditions | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-004459-19 | Sponsor Protocol Number: CDRB436G2401 | Start Date*: 2019-07-31 |
| Sponsor Name:Novartis Farmacéutica S.A. | ||
| Full Title: An open label, multi-center roll-over study to assess long-term effect in pediatric patients treated with Tafinlar (dabrafenib) and/or Mekinist (trametinib) | ||
| Medical condition: Children and Adolescents with Cancers Harboring V600 mutations | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
